Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies

[1]  A. Bredenoord,et al.  Gastro-oesophageal reflux disease , 2000, The Lancet.

[2]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[3]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[4]  D. Corley,et al.  Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. , 2010, Gastroenterology.

[5]  B. Mcgowan,et al.  Prescribing of anti‐osteoporotic therapies following the use of proton pump inhibitors in general practice , 2010, Pharmacoepidemiology and drug safety.

[6]  C. Cooper,et al.  Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study , 2010, Osteoporosis International.

[7]  J. Manson,et al.  Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. , 2010, Archives of internal medicine.

[8]  L. Lix,et al.  Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. , 2010, Gastroenterology.

[9]  C. Cooper,et al.  Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates , 2009, Osteoporosis International.

[10]  F. Chan,et al.  Guidelines for Prevention of NSAID-Related Ulcer Complications , 2009, The American Journal of Gastroenterology.

[11]  D. Bauer,et al.  Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults , 2008, Calcified Tissue International.

[12]  L. Lix,et al.  Use of proton pump inhibitors and risk of osteoporosis-related fractures , 2008, Canadian Medical Association Journal.

[13]  H. Jick,et al.  Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors , 2008, Pharmacotherapy.

[14]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[15]  D. Felsenberg,et al.  Increase in Vertebral Fracture Risk in Postmenopausal Women Using Omeprazole , 2008, Calcified Tissue International.

[16]  Andrew Herxheimer,et al.  Systematic reviews of adverse effects: framework for a structured approach , 2007, BMC medical research methodology.

[17]  Suzanne G. Leveille,et al.  Relationship of homocysteine levels to quadriceps strength, gait speed, and late-life disability in older adults. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[18]  A. Tosteson,et al.  Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025 , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  Yu-Xiao Yang,et al.  Long-term proton pump inhibitor therapy and risk of hip fracture. , 2006, JAMA.

[20]  I. Olkin,et al.  The case of the misleading funnel plot , 2006, BMJ : British Medical Journal.

[21]  P. Vestergaard,et al.  Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture , 2006, Calcified Tissue International.

[22]  P. Moayyedi,et al.  Gastro-oesophageal reflux disease , 2021, Nature Reviews Disease Primers.

[23]  A. Murray,et al.  Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. , 2005, The American journal of medicine.

[24]  K. Abe,et al.  Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans , 1993, Calcified Tissue International.

[25]  J. Pérez-Castrillón,et al.  Homocysteine as a predictive factor for hip fracture in older persons. , 2004, The New England journal of medicine.

[26]  E. Roughead,et al.  Bisphosphonate use and subsequent prescription of acid suppressants. , 2004, British journal of clinical pharmacology.

[27]  A. Hofman,et al.  Homocysteine levels and the risk of osteoporotic fracture. , 2004, The New England journal of medicine.

[28]  R. Valuck,et al.  A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. , 2004, Journal of clinical epidemiology.

[29]  T. Seeman,et al.  Homocysteine levels and decline in physical function: MacArthur Studies of Successful Aging. , 2002, The American journal of medicine.

[30]  Rebecca S. Graves,et al.  Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. , 2002 .

[31]  Christopher J Cates,et al.  Simpson's paradox and calculation of number needed to treat from meta-analysis , 2002, BMC medical research methodology.

[32]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[33]  David Moher,et al.  Meta-analysis of Observational Studies in Epidemiology , 2000 .

[34]  H. Blom,et al.  Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. , 1996, Biochimica et biophysica acta.